Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs PTC 596 (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 24 Jun 2019 Planned End Date changed from 1 Jun 2022 to 1 Feb 2024.
- 24 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2021.
- 31 Aug 2018 Biomarkers information updated